<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">50975</article-id><article-id pub-id-type="doi">10.26442/00403660.2020.10.000393</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association of polymorphisms of genes TCF7L2, FABP2, KCNQ1, ADIPOQ with the prognosis of the development of type 2 diabetes mellitus</article-title><trans-title-group xml:lang="ru"><trans-title>Ассоциация полиморфизмов генов TCF7L2, FABP2, KCNQ1, ADIPOQ с прогнозом развития сахарного диабета 2-го типа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9033-1588</contrib-id><name-alternatives><name xml:lang="en"><surname>Mel’nikova</surname><given-names>E. S.</given-names></name><name xml:lang="ru"><surname>Мельникова</surname><given-names>Елизавета Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>ординатор НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4095-0169</contrib-id><name-alternatives><name xml:lang="en"><surname>Rymar</surname><given-names>O. D.</given-names></name><name xml:lang="ru"><surname>Рымар</surname><given-names>Оксана Дмитриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., зав. лаб. клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9460-6294</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>Анастасия Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>к.м.н., мл. науч. сотр. лаб. молекулярно-генетических исследований терапевтических заболеваний НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4716-876X</contrib-id><name-alternatives><name xml:lang="en"><surname>Mustafina</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Мустафина</surname><given-names>Светлана Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., ст. науч. сотр. лаб. клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8577-8801</contrib-id><name-alternatives><name xml:lang="en"><surname>Shapkina</surname><given-names>M. Ju.</given-names></name><name xml:lang="ru"><surname>Шапкина</surname><given-names>Марина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>мл. науч. сотр. лаб. этиопатогенеза и клиники внутренних заболеваний НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2357-5918</contrib-id><name-alternatives><name xml:lang="en"><surname>Bobak</surname><given-names>Martin</given-names></name><name xml:lang="ru"><surname>Бобак</surname><given-names>Мартин</given-names></name></name-alternatives><address><country country="AI">Anguilla</country></address><bio xml:lang="ru"><p>проф. эпидемиологии, зам. рук. отд. эпидемиологии и общественного здоровья Университетского колледжа</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6539-0466</contrib-id><name-alternatives><name xml:lang="en"><surname>Maljutina</surname><given-names>S. K.</given-names></name><name xml:lang="ru"><surname>Малютина</surname><given-names>Софья Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., проф., зав. лаб. этиопатогенеза и клиники внутренних заболеваний НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9425-413X</contrib-id><name-alternatives><name xml:lang="en"><surname>Voevoda</surname><given-names>M. I.</given-names></name><name xml:lang="ru"><surname>Воевода</surname><given-names>Михаил Иванович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, д.м.н., проф., НИИТПМ – филиал ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7165-4496</contrib-id><name-alternatives><name xml:lang="en"><surname>Maksimov</surname><given-names>V. N.</given-names></name><name xml:lang="ru"><surname>Максимов</surname><given-names>Владимир Николаевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д.м.н., проф., зав. лаб. молекулярно-генетических исследований терапевтических заболеваний НИИТПМ – филиала ФГБНУ ИЦиГ</p></bio><email>jarinaleksi@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Internal and Preventive Medicine</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт терапии и профилактической медицины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Department of Epidemiology &amp; Public Health, University College London</institution></aff><aff><institution xml:lang="ru">Отдел эпидемиологии и общественного здоровья Университетского колледжа Лондона</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2020</year></pub-date><volume>92</volume><issue>10</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>40</fpage><lpage>47</lpage><history><date date-type="received" iso-8601-date="2020-11-23"><day>23</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-11-23"><day>23</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/50975">https://ter-arkhiv.ru/0040-3660/article/view/50975</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To study the possibility of using polymorphisms of genes <italic>TCF7L2</italic>, <italic>FABP2</italic>, <italic>KCNQ1</italic>, <italic>ADIPOQ</italic> as markers for predicting the development of type 2 diabetes mellitus (T2D) in the population of Novosibirsk.</p> <p><bold>Materials and methods. </bold>On the basis of prospective observation of a representative population sample of residents of Novosibirsk (HAPIEE), 2 groups were formed according to the “case-control” principle (case – people who had diabetes mellitus 2 over 10 years of observation, and control – people who did not developed disorders of carbohydrate metabolism). T2D group (<italic>n</italic>=443, mean age 56.2±6.7 years, men – 29.6%, women – 70.4%), control group (<italic>n</italic>=532, mean age 56.1±7.1 years, men – 32.7%, women – 67.3%). DNA was isolated by phenol-chloroform extraction. Genotyping was performed by the method of polymerase chain reaction with subsequent analysis of restriction fragment length polymorphism, polymerase chain reaction in real time. Statistical processing was carried out using the SPSS 16.0 software package.</p> <p><bold>Results and discussion. </bold>No significant effect of rs1799883 of the <italic>FABP2</italic> gene, rs2237892 of the <italic>KCNQ1</italic> gene, and rs6773957 of the <italic>ADIPOQ</italic> gene on the risk of developing T2D was found. Genotypes TT and TC rs7903146 of the <italic>TCF7L2</italic> gene are genotypes for the risk of developing T2D (relative risk – RR 3.90, 95% confidence interval – CI 2.31–6.61, <italic>p</italic>&lt;0.001; RR 1.86, 95% CI 1.42–2.43, <italic>p</italic>&lt;0.001, respectively). The CC genotype rs7903146 of the <italic>TCF7L2</italic> gene is associated with a protective effect against T2D (RR 0.37, 95% CI 0.29–0.49, <italic>p</italic>&lt;0.001). When the <italic>TCF7L2</italic> gene is included in the model for assessing the risk of developing T2D rs7903146, it retains its significance in both men and women.</p> <p><bold>Conclusion. </bold>The rs7903146 polymorphism of the <italic>TCF7L2</italic> gene confirmed its association with the prognosis of the development of T2D, which indicates the possibility of considering it as a candidate for inclusion in a diabetes risk meter. Variants of risk meters have been developed to assess the prognosis of the development of diabetes mellitus 2 in men and women aged 45–69 years during 10 years of follow-up. The association with the prognosis of the development of T2D polymorphisms rs1799883 of the <italic>FABP2</italic> gene, rs2237892 of the <italic>KCNQ1</italic> gene and rs6773957 of the <italic>ADIPOQ</italic> gene was not found.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Изучить возможность использования в популяции г. Новосибирска в качестве маркеров прогноза развития сахарного диабета 2-го типа (СД 2) полиморфизмов генов <italic>TCF7L2</italic>, <italic>FABP2</italic>, <italic>KCNQ1</italic>, <italic>ADIPOQ</italic>.</p> <p><bold>Материалы и методы. </bold>На основе проспективного наблюдения репрезентативной популяционной выборки жителей Новосибирска (HAPIEE) сформированы 2 группы по принципу «случай–контроль» (случай – лица, у которых за 10 лет наблюдения выявлен СД 2, и контроль – лица, у которых за 10-летний период не развились нарушения углеводного обмена). Группа СД 2 (<italic>n</italic>=443, средний возраст 56,2±6,7 года, мужчины – 29,6%, женщины – 70,4%), группа контроля (<italic>n</italic>=532, средний возраст 56,1±7,1 года, мужчины – 32,7%, женщины – 67,3%). ДНК выделена методом фенол-хлороформной экстракции. Генотипирование выполнено методом полимеразной цепной реакции с последующим анализом полиморфизма длин рестрикционных фрагментов, полимеразной цепной реакции с обратной транскрипцией. Статистическая обработка проведена с использованием программного пакета SPSS 16.0.</p> <p><bold>Результаты и обсуждение.</bold> Не обнаружено значимого влияния rs1799883 гена <italic>FABP2</italic>, rs2237892 гена <italic>KCNQ1</italic> и rs6773957 гена <italic>ADIPOQ</italic> на риск развития СД 2. Генотипы ТТ и TC rs7903146 гена <italic>TCF7L2</italic> являются генотипами риска развития СД 2 (относительный риск – ОР 3,90, 95% доверительный интервал – ДИ 2,31–6,61, <italic>р</italic>&lt;0,001; ОР 1,86, 95% ДИ 1,42–2,43, <italic>р</italic>&lt;0,001 соответственно). Генотип СС rs7903146 гена <italic>TCF7L2</italic> ассоциирован с протективным эффектом в отношении СД 2 (ОР 0,37, 95% ДИ 0,29–0,49, <italic>р</italic>&lt;0,001). При включении в модель оценки риска развития СД 2 rs7903146 гена <italic>TCF7L2</italic> он сохраняет свою значимость и у мужчин, и у женщин.</p> <p><bold>Заключение.</bold> Полиморфизм rs7903146 гена <italic>TCF7L2</italic> подтвердил свою ассоциацию с прогнозом развития СД 2, что указывает на возможность его рассмотрения в качестве кандидата на внесение в рискометр СД 2. Разработаны варианты рискометров для оценки прогноза развития СД 2 у мужчин и женщин в возрасте 45–69 лет в течение 10 лет наблюдения. Ассоциация с прогнозом развития СД 2 полиморфизмов rs1799883 гена <italic>FABP2</italic>, rs2237892 гена <italic>KCNQ1</italic> и rs6773957 гена <italic>ADIPOQ</italic> – не обнаружена.</p></trans-abstract><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>single nucleotide polymorphism</kwd><kwd>rs7903146</kwd><kwd>TCF7L2</kwd><kwd>rs1799883</kwd><kwd>FABP2</kwd><kwd>rs2237892</kwd><kwd>KCNQ1</kwd><kwd>rs6773957</kwd><kwd>ADIPOQ</kwd><kwd>prognosis</kwd><kwd>risk meter</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сахарный диабет 2-го типа</kwd><kwd>однонуклеотидный полиморфизм</kwd><kwd>rs7903146</kwd><kwd>TCF7L2</kwd><kwd>rs1799883</kwd><kwd>FABP2</kwd><kwd>rs2237892</kwd><kwd>KCNQ1</kwd><kwd>rs6773957</kwd><kwd>ADIPOQ</kwd><kwd>прогноз</kwd><kwd>рискометр</kwd></kwd-group><funding-group><funding-statement xml:lang="en">Grant WT 064947 / Z / 01 / Z; 081081 / Z / 06 / Z; NIA, USA (1R01 AG23522). The budgetary theme for the State Assignment No. 0324-2018-0002 and No. 0324-2017-0048.</funding-statement><funding-statement xml:lang="ru">Грант WT 064947/Z/01/Z; 081081/Z/06/Z; NIA, USA (1R01 AG23522). Бюджетная тема по Государственному заданию №0324-2018-0002 и №0324-2017-0048.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabet Res Clin Pract. 2018;138:271-81. doi: 10.1016/j.diabres.2018.02.023</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Воевода М.И., Иванова А.А., Шахтшнейдер Е.В. и др. Молекулярная генетика MODY. Терапевтический архив. 2016;88(4):117-24 [Voevoda MI, Ivanova AA, Shahtshnejder EV, et al. Molekular genetics of maturity-onset diabetes of the young. Therapeutic Arhive. 2016;88(4):117-24 (In Russ.)]. doi: 10.17116/terarkh2016884117-124</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>OMIM. Accessed May 14, 2019. http://omim.org/</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>HuGE Navigator. Accessed May 14, 2019. http://www.cdc.gov/genomics/hugenet/hugenavigator.htm</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sikhayeva N, Iskakova A, Saigi-Morgui N, et al. Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study. BMC medical genetics. 2017;18(1):76. doi: 10.1186/s12881-017-0443-2</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Мустафина С.В., Симонова Г.И., Рымар О.Д. Сравнительная характеристика шкал риска сахарного диабета 2 типа. Сахарный диабет. 2014;3:17-22. [Mustafina SV, Simonova GI, Rymar OD. Comparative characteristics of diabetes risk scores. Diabetes Mellitus. 2014;3:17-22 (In Russ.)]. doi: 10.14341/DM2014317-22</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wang J, Stancáková A, Kuusisto J, Laakso M. Identification of undiagnosed type 2 diabetic individuals by the finnish diabetes risk score and biochemical and genetic markers: a population-based study of 7232 Finnish men. J Clin Endocrin Metab. 2010;95(8):3858-62. doi: 10.1210/ jc.2010-0012</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Мустафина С.В., Рымар О.Д., Сазонова О.В. и др. Валидизация финской шкалы риска «FINDRISC» на европеоидной популяции Сибири. Сахарный диабет. 2016;19(2):113-8 [Mustafina SV, Rymar OD, Sazonova OV, et al. Validation of the Finnish diabetes risk score (FINDRISC) for the Caucasian population of Siberia. Diabetes Mellitus. 2016;19(2):113-8 (In Russ.)]. doi: 10.14341/DM200418-10</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mühlenbruch K, Jeppesen C, Joost HG, et al. The value of genetic information for diabetes risk prediction – differences according to sex, age, family history and obesity. PLoS One. 2013;8(5):e64307. doi: 10.1371/journal.pone.0064307</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Goto A, Noda M, Goto M, et al.; JPHC Study Group. Predictive performance of a genetic risk score using 11 susceptibility alleles for the incidence of Type 2 diabetes in a general Japanese population: a nested case-control study. Diabetic Med: J British Diabetic Assotiation. 2018;35(5):602-11. doi: 10.1111/dme.13602</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Lin X, Song K, Lim N, et al. Risk prediction of prevalent diabetes in a Swiss population using a weighted genetic score – the CoLaus Study. Diabetologia. 2009;52(4):600-8. doi: 10.1007/s00125-008-1254-y</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359(21):2208-19. doi: 10.1056/NEJMoa0804742</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359(21):2220-32. doi: 10.1056/NEJMoa0801869</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Abbas S, Raza ST, Chandra A, et al. Association of ACE, FABP2 and GST genes polymorphism with essential hypertension risk among a North Indian population. Ann Hum Biol. 2015;42(5):461-9. doi: 10.3109/03014460.2014.968206</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Орлов П.С., Иванощук Д.Е., Михайлова С.В. и др. Исследование ассоциаций новых генетических маркеров сахарного диабета второго типа на Западно-Сибирской популяции европеоидов. Сибирский научный мед. журн. 2015;35(2):74-9 [Orlov PS, Ivanoshchuk DI, Mikhaylova SV, et al. Association study of new genetic markers of type 2 diabets mellitus in West Siberian Caucasian population. Sibirskii nauchnyi med. zhurn. 2015;35(2):74-9 (In Russ.)].</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ding W, Xu L, Zhang L, et al. Meta-analysis of association between TCF7L2 polymorphism rs7903146 and type 2 diabetes mellitus. BMC Med Genetics. 2018;19(1):38. doi: 10.1186/s12881-018-0553-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genetics 2006;38(3):320-3. doi: 10.1038/ng1732</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cauchi S, Meyre D, Choquet H, et al.; DESIR Study Group. Transcription factor TCF7L2 genetic study in the french population. Diabetes. 2006;55(10):2903-8. doi: 10.2337/db06-0474</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Yan Y, North KE, Ballantyne CM, et al. Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in african american and caucasian adults the atherosclerosis risk in communities study. Diabetes. 2009;58(1):285-9. doi: 10.2337/db08-0569</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Horikoshi M, Hara K, Ito C, et al. A genetic variation of the transcription factor 7-like 2 gene is associated with risk of type 2 diabetes in the Japanese population. Diabetologia. 2007;50(4):747-51. doi: 10.1007/s00125-006-0588-6</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Barra GB, Dutra LAS, Watanabe S, et al. Association of the rs7903146 single nucleotide polymorphism at the transcription factor 7-like 2 (TCF7L2) locus with type 2 diabetes in brazilian subjects. Arq Bras Endocrinol Metabol. 2012;56(8):479-84. doi: 10.1590/S0004-27302012000800003</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Meng Q, Ge S, Yan W, et al. Screening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using maldi-tof ms. Proteomics. Clin Applicat. 2017;11(3-4). doi: 10.1002/prca.201600079</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Бондарь И.А., Филипенко М.Л., Шабельникова О.Ю., Соколова Е.А. Ассоциация полиморфных маркеров rs7903146 гена TCF7L2 и rs1801282 гена PPARG (PRO12ALA) с сахарным диабетом 2 типа в Новосибирской области. Сахарный диабет. 2013;4:17-22 [Bondar’ IA, Filipenko ML, Shabel’nikova OJu, Sokolova EA. Rs7903146 variant of TCF7L2 gene and rs18012824 variant of PPARG2 gene (Pro12Ala) are associated with type 2 diabetes mellitus in Novosibirsk population. Diabetes Mellitus. 2013;4:17-22 (In Russ.)]. doi: 10.14341/dm2013417-22</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>World Health Organization. Fact files: ten facts on obesity. 2016. Accessed May 14, 2019. https://www.who.int/features/factfiles/obesity/en/</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Qiu CJ, Ye XZ, Yu XJ, et al. Association between FABP2 Ala54Thr polymorphisms and type 2 diabetes mellitus risk: a HuGE Review and Meta-Analysis. J Cell Molecul Med. 2014;18(12):2530-5. doi: 10.1111/jcmm.12385</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Liu Y, Wu G, Han L, et al. Association of the FABP2 Ala54Thr polymorphism with type 2 diabetes, obesity, and metabolic syndrome: a population-based case-control study and a systematic meta-analysis. Genetics and molecular research: GMR. 2015;14(1):1155-68. doi: 10.4238/2015</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Zhao T, Zhao J, Yang W. Association of the fatty acid-binding protein 2 gene Ala54Thr polymorphism with insulin resistance and blood glucose: a meta-analysis in 13451 subjects. Diabetes/metabolism Res Rev. 2010;26(5):357-64. doi: 10.1002/dmrr.1085</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Li YY, Wang XM, Lu XZ. KCNQ1 rs2237892 C→T gene polymorphism and type 2 diabetes mellitus in the Asian population: a meta-analysis of 15,736 patients. J Cell Molecul Med. 2014;18(2):274-82. doi: 10.1111/jcmm.12185.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Liu Y, Zhou DZ, Zhang D, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes in the population of mainland China. Diabetologia. 2009;52(7):1315-21. doi: 10.1007 / s00125-009-1375-y</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Han X, Luo Y, Ren Q, et al. Implication of genetic variants near SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, FTO, TCF2, ¬KCNQ1, and WFS1 in type 2 diabetes in a Chinese population. BMC Med Genetics. 2010;11:81. doi: 10.1186/1471-2350-11-81</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genetics. 2008;40(9):1098-102. doi: 10.1038/ng.208</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Jonsson AA, Isomaa B, Tuomi T, et al. Variant in the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin secretion. Diabetes. 2009;58(10):2409-13. doi: 10.2337/db09-0246</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Hu C, Wang C, Zhang R, et al. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia. 2009;52(7):1322-5. doi: 10.1007/s00125-009-1335-6</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Zhou Q, Chen B, Ji T, et al. Association of genetic variants in RETN, NAMPT and ADIPOQ gene with glycemic, metabolic traits and diabetes risk in a Chinese population. Gene. 2018;642:439-46. doi: 10.1016/j.gene.2017.10.084</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Qian Y, Dong M, Lu F, et al. Joint effect of CENTD2 and KCNQ1 polymorphisms on the risk of type 2 diabetes mellitus among Chinese Han population. Mol Cell Endocrinol. 2015;407:46-51. doi: 10.1016/j.mce.2015.02.026</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Lee YH, Kang ES, Kim SH, et al. Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. J Hum Genetics. 2008;53(11-12):991-8. doi: 10.1007/s10038-008-0341-8</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genetics. 2008;40(9):1092-7. doi: 10.1038/ng.207</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Mussig K, Staiger H, Machicao F, et al. Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes. 2009;58(7):1715-20. doi: 10.2337/db08-1589</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Been LF, Ralhan S, Wander GS, et al. Variants in KCNQ1 increase type II diabetes susceptibility in South Asians: a study of 3,310 subjects from India and the US. BMC Med Genetics. 2011;12:18. doi: 10.1186/1471-2350-12-18</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Chu H, Wang M, Zhong D, et al. ADIPOQ polymorphisms are associated with type 2 diabetes mellitus: a meta-analysis study. Diabetes Metab Res Rev. 2013;29(7):532-45. doi: 10.1002/dmrr.2424</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Goto A, Noda M, Goto M, et al.; JPHC Study Group. Plasma adiponectin levels, ADIPOQ variants, and incidence of type 2 diabetes: A nested case-control study. Diabetes Res Clin Pract. 2017;127:256-64. doi: 10.1016/j.diabres.2017.03.020</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Ramya K, Ayyappa KA, Ghosh S, et al. Genetic association of ADIPOQ gene variants with type 2 diabetes, obesity and serum adiponectin levels in south Indian population. Gene. 2013;532(2):253-62. doi: 10.1016/j.gene.2013.09.012</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Малютина С.К., Максимов В.Н., Орлов П.С. и др. Ассоциации артериального давления и артериальной гипертензии с генетическими маркерами, отобранными по данным полногеномных исследований. Рус. журн. кардиологии. 2018;23(10):8–13 [Malyutina SK, Maksimov VN, Orlov PS, et al. The association of blood pressure and hypertension with genetic markers identified in genome-wide association studies. Russian Journal of Cardiology. 2018;23(10):8–13 (In Russ.)]. doi: 10.15829/1560-4071-2018-10-8-13</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Menzaghi C, Salvemini L, Paroni G, et al. Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study. J Int Med. 2010;267(3):287-94. doi: 10.1111/j.1365-2796.2009.02141</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Siitonen N, Pulkkinen L, Lindström J, et al. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genetics. 2011;12:5. doi: 10.1186/1471-2350-12-5</mixed-citation></ref></ref-list></back></article>
